Ftse Mib
34.660,38
-0,50%
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
NASDAQ
17.133,13
-0,23%
Bitcoin
69.309,83
-0,03%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cyclacel Pharmaceuticals Inc (CYCC) Cyclacel Pharmaceuticals Inc (CYCC) Notizie

CYCC

Cyclacel Pharmaceuticals (CYCC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYCC
DataOraFonteTitoloSimboloCompagnia
04/06/202414:00GlobeNewswire Inc.Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/06/202414:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/05/202422:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
08/05/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
02/05/202422:30GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/04/202419:51AllPennyStocks.com$8 Million Private Placement Announcement Sends Biotech FlyingNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/04/202413:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:CYCCCyclacel Pharmaceuticals Inc
01/04/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
19/03/202421:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
19/03/202412:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:CYCCCyclacel Pharmaceuticals Inc
13/03/202421:05GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
07/03/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:CYCCCyclacel Pharmaceuticals Inc
06/03/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditNASDAQ:CYCCCyclacel Pharmaceuticals Inc
20/02/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/01/202415:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical OfficerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
18/12/202315:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP DeletionsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
12/12/202322:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Reverse Stock SplitNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/11/202315:15GlobeNewswire Inc.Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SECNASDAQ:CYCCCyclacel Pharmaceuticals Inc
28/11/202323:15GlobeNewswire Inc.Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-QNASDAQ:CYCCCyclacel Pharmaceuticals Inc
07/11/202315:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
09/08/202322:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/08/202315:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/06/202322:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
11/05/202323:16Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
04/05/202315:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/05/202315:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax CreditNASDAQ:CYCCCyclacel Pharmaceuticals Inc
08/03/202323:03Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/02/202322:56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
06/02/202317:27Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
02/02/202322:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYCC

La tua Cronologia

LSE
51FA
Lon.quad.hse.49
BOV
IFCM3
Infracommerce Caxaas ON
LSE
RE48
Bank Nova 34
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network